THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN), today announced results of voting at the company's Annual Meeting of
Stockholders, held at The St. Regis Hotel, San Francisco, Calif.
Approximately 87.3 percent of outstanding shares were represented at the
The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de
Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C.
Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D.
Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of
Directors, each receiving a majority of "For" votes of the votes cast. Each
was elected by no less than 86.7 percent of the votes cast. With the
reelection of these directors, Amgen currently has 12 directors.
With approximately 98.7 percent of "For" votes of the votes cast,
stockholders ratified Ernst & Young LLP as Amgen's independent registered
public accountants for the year ending Dec. 31, 2009.
Stockholders approved the Amgen 2009 Equity Incentive Plan, which
authorizes the issuance of up to 100,000,000 shares of Amgen common stock. The
proposal was approved with approximately 81.2 percent of votes cast "For."
Stockholders approved the proposed amendment to the company's Restated
Certificate of Incorporation, as amended, to reduce the sixty-six and
two-thirds percent (66-2/3%) voting requirement in the company's Restated
Certificate of Incorporation, as amended, to a simple majority voting
requirement for approval of certain business combinations. Approximately 84.4
percent of the outstanding shares of our common stock were in favor of the
Stockholders approved a nonbinding resolution recommending that the
company amend its Amended and Restated Bylaws, as amended, to permit holders
of 10 percent of the company's outstanding common stock the ability to call
special meetings. The proposal received approximately 59.5 percent of the
votes cast "For" the proposal. Stockholders rejected the proposal requesting
that the company change its jurisdiction of incorporation from Delaware to
North Dakota. The proposal received less than 3.2 percent of the votes cast
"For" the proposal.
The final vote totals will be included in the company's second quarter
periodic report to be filed with the Securities and Exchange Commission.
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe and effective
medicines from lab, to manufacturing plant, to patient. Amgen therapeutics
have changed the practice of medicine, helping millions of people around the
world in the fight against cancer, kidney disease, rheumatoid arthritis and
other serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
David Polk: 805-447-4613 (media)
Arvind Sood: 805-447-1060 (investors)